240 related articles for article (PubMed ID: 27089417)
1. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
Anavi-Goffer S; Irving AJ; Ross RA
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
[TBL] [Abstract][Full Text] [Related]
2. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
[TBL] [Abstract][Full Text] [Related]
3. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
[TBL] [Abstract][Full Text] [Related]
4. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
Sharir H; Abood ME
Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
[TBL] [Abstract][Full Text] [Related]
7. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Nevalainen T; Irving AJ
Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
[TBL] [Abstract][Full Text] [Related]
8. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
[TBL] [Abstract][Full Text] [Related]
9. GPR55 ligands promote receptor coupling to multiple signalling pathways.
Henstridge CM; Balenga NA; Schröder R; Kargl JK; Platzer W; Martini L; Arthur S; Penman J; Whistler JL; Kostenis E; Waldhoer M; Irving AJ
Br J Pharmacol; 2010 Jun; 160(3):604-14. PubMed ID: 20136841
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
[TBL] [Abstract][Full Text] [Related]
11. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
[TBL] [Abstract][Full Text] [Related]
12. GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans.
Liu B; Song S; Ruz-Maldonado I; Pingitore A; Huang GC; Baker D; Jones PM; Persaud SJ
Diabetes Obes Metab; 2016 Dec; 18(12):1263-1273. PubMed ID: 27561953
[TBL] [Abstract][Full Text] [Related]
13. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.
Smoum R; Baraghithy S; Chourasia M; Breuer A; Mussai N; Attar-Namdar M; Kogan NM; Raphael B; Bolognini D; Cascio MG; Marini P; Pertwee RG; Shurki A; Mechoulam R; Bab I
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8774-9. PubMed ID: 26124120
[TBL] [Abstract][Full Text] [Related]
14. A Functional Assay for GPR55: Envision Protocol.
Anavi-Goffer S; Ross RA
Methods Mol Biol; 2016; 1412():77-83. PubMed ID: 27245893
[TBL] [Abstract][Full Text] [Related]
15. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.
Balenga NA; Martínez-Pinilla E; Kargl J; Schröder R; Peinhaupt M; Platzer W; Bálint Z; Zamarbide M; Dopeso-Reyes IG; Ricobaraza A; Pérez-Ortiz JM; Kostenis E; Waldhoer M; Heinemann A; Franco R
Br J Pharmacol; 2014 Dec; 171(23):5387-406. PubMed ID: 25048571
[TBL] [Abstract][Full Text] [Related]
16. Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning.
Mosca MG; Mangini M; Cioffi S; Barba P; Mariggiò S
Cell Commun Signal; 2021 Apr; 19(1):48. PubMed ID: 33902596
[TBL] [Abstract][Full Text] [Related]
17. Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists.
Ribeiro R; Wen J; Li S; Zhang Y
Prostaglandins Other Lipid Mediat; 2013 Jan; 100-101():1-14. PubMed ID: 23219970
[TBL] [Abstract][Full Text] [Related]
18. The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis.
Hofmann NA; Yang J; Trauger SA; Nakayama H; Huang L; Strunk D; Moses MA; Klagsbrun M; Bischoff J; Graier WF
Br J Pharmacol; 2015 Aug; 172(16):4107-18. PubMed ID: 25989290
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
Obara Y; Ueno S; Yanagihata Y; Nakahata N
PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]